Long-term safety study of LB-102 in adults with schizophrenia
Tests LB-102 for long-term safety in adults with stable schizophrenia.
Plain-language title generated from the registry record
Registry title: 52-week Open Label Safety-Tolerability Study
Key facts
- Where
- Anaheim, Atlanta, Bentonville, Canton, Cerritos, Chandler, Chicago, Culver City, DeSoto, Gaithersburg, Hollywood, Las Vegas, Little Rock, Miami Lakes, New York, Philadelphia, Richardson, San Diego, Snellville, St Louis, and West Palm Beach, United StatesSee the 23 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07369154, who can take part
Where in United States
- Advanced Research CenterAnaheim, United StatesTaking people
- CenExelAtlanta, United StatesTaking people
- Pillar Clinical ResearchBentonville, United StatesTaking people
- Neuro-Behavioral Clinical ResearchCanton, United StatesTaking people
- Synapse Clinical TrialsCerritos, United StatesTaking people
- Chandler Clinical TrialsChandler, United StatesTaking people
- Pillar Clinical ResearchChicago, United StatesTaking people
- CenExelCulver City, United StatesTaking people
- ProScience Research GroupCulver City, United StatesTaking people
- Adams ClinicalDeSoto, United StatesTaking people
- CenExel GaithersburgGaithersburg, United StatesTaking people
- CenExelHollywood, United StatesTaking people
- Redbird ResearchLas Vegas, United StatesTaking people
- Pillar Clinical ResearchLittle Rock, United StatesTaking people
- Woodland International Research GroupLittle Rock, United StatesTaking people
- Segal TrialsMiami Lakes, United StatesTaking people
- Neuro-Behavioral Clinical ResearchNew York, United StatesTaking people
- Adams ClinicalPhiladelphia, United StatesTaking people
- Pillar Clinical ResearchRichardson, United StatesTaking people
- Synergy San DiegoSan Diego, United StatesTaking people
- Accelerated Clinical TrialSnellville, United StatesTaking people
- Arch Clinical TrialsSt Louis, United StatesTaking people
- Health Synergy Clinical ResearchWest Palm Beach, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- LB Pharmaceuticals Inc.
- Trial code
- NCT07369154
- Record updated
- 9 September 2026
- Original description
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophreniaRead full original descriptionShow less
A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
Inclusion: Provide ICF; Patients clinically stable PANSS </= 80 at screening; CGI-S </+ 3 at screening; Medically stable; BMI 18 -40; Taking oral antipsychotic treatment for at least 30 days; Have stable living environment.
Exclusion: History of treatment resistance to schizophrenia medications; History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other; Sexually active M/F patients not willing to use highly effective contraception; Breast feeding; DSM-5 current diagnosis other than schizophrenia; Risk of suicidal behavior.